Form Type: 4

SEC EDGAR Link
Accession Number:0001104659-20-071838
Date:2020-06-10
Issuer: STEMLINE THERAPEUTICS INC (STML)
Original Submission Date:

Reporting Person:

HUME DANIEL
C/O STEMLINE THERAPEUTICS, INC.
750 LEXINGTON AVENUE, ELEVENTH FLOOR NEW YORK, NY 10022

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-06-10 U 35,468 d $0.00 0 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among issuer, berlin-chemie ag, and mercury merger sub, inc., dated as of may 3, 2020, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("cvr") per share. each cvr represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of elzonris in any one of certain countries following a marketing authorization approval by the european commission. the cvr milestone must be achieved on or prior to december 31, 2021.
WhaleWisdom Logo

Elevate your investments